Clin2
NCT06410599Possibly a fitRecruiting

Medication boost for tough-to-treat chronic depression

Major Depressive Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests a new medication added to your current treatment for chronic depression that hasn't gotten better with at least two antidepressants and 12 therapy sessions. It might help when standard treatments aren't enough.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years to 64 years
Study type
Interventional

Who can take part

  • You are between 18 and 64 years old.
  • You have been diagnosed with chronic depression—either recurrent episodes without full recovery, or a single episode lasting two years or more.
  • You have tried at least two different antidepressants from two different medication classes, and they didn't work well enough.
  • You have completed at least 12 sessions of therapy (like cognitive behavioral therapy) for your depression.
  • You are not currently struggling with substance misuse as a primary problem, and you have no serious medical conditions like uncontrolled high blood pressure, epilepsy, or recent heart problems.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05973851Recruiting· Phase 3
Six-week medicine boost for depression after first treatment failure

This study tests a more intensive antidepressant medicine approach for people whose first tried treatment didn’t work well enough. It compares the intensified treatment with usual care, aiming to improve depression symptoms and daily functioning.

Innsbruck
NCT07088380Recruiting· Phase 3
Ketamine combined with ECT for hard-to-treat depression

This trial tests whether adding ketamine to electroconvulsive therapy (ECT) works better than ECT alone for people with depression that hasn't improved with at least two different antidepressants. It may offer a new option for those who have not found relief from standard treatments.

Milan
NCT03973268Recruiting· Phase 1
Ketamine study to understand treatment response in hard-to-treat depression

This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.

Bethesda, Maryland
NCT03065335Recruiting· Phase 1
Ketamine plus brain imaging to study response in depression

This early-stage study tests how ketamine given once and then repeatedly may change brain signals and related biomarkers in people with major depression. If you’re eligible, the team will use brain imaging and assessments to see who responds and why.

Bethesda, Maryland
NCT05327699Recruiting· Early Phase 1
Ketamine study for depression with reduced pleasure

This early-phase study tests whether ketamine can help people with major depression who have trouble feeling pleasure. It also studies how the brain may change in response to stress, to better understand who might respond to treatment.

Atlanta, Georgia
NCT06559826Recruiting· Phase 2
Ketamine therapy with or without talk for depression

This study compares ketamine alone to ketamine combined with psychotherapy for treating depression. It may help if you have moderate to severe depression and want to see if adding talk therapy improves results.

New York, New York

Hear when a new Major Depressive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.